Mesoblast (ASX:MSB) Edges Higher to A$2.08, Trims Weekly Losses

Aditi Sarkar

04 March 2026 01:09 PM AEDT

Mesoblast (ASX:MSB) Edges Higher to A$2.08, Trims Weekly Losses

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

Mesoblast Ltd (ASX: MSB) rose 3.23% to A$2.08 on March 4, 2026.
The stock remains down 13.39% over the past five trading sessions.
H1 FY2026 revenue increased to US$51.3 million from US$3.2 million year-on-year.
Ryoncil® generated US$57.0 million in gross sales during the half year.
The company expects FY2026 Ryoncil® net revenue between US$110 million and US$120 million.

Mesoblast Limited (ASX:MSB) (Nasdaq:MESO) traded at A$2.08 as of 12:38 pm on March 4, 2026, marking a 3.23% gain for the session. The advance comes amid recent volatility, with the stock still down 13.39% over the past five days.

Half-Year Revenue Reflects Commercial Rollout

For H1 FY2026, Mesoblast reported total revenue of US$51.3 million (A$78.3 million), compared to US$3.2 million in the prior corresponding period.

The increase followed the commercial launch of Ryoncil® (remestemcel-L-rknd) in the United States. The therapy generated gross sales of US$57.0 million and revenue of US$48.7 million after gross-to-net adjustments.

Ryoncil® delivered gross profit of US$44.2 million, excluding amortization, compared with nil in the prior year period. Direct selling costs totaled US$7.7 million.

The company reported a net loss of US$40.2 million, compared with US$47.9 million in the previous corresponding period. Excluding a US$23.0 million inventory reversal recorded last year, the year-on-year improvement in net loss would have been US$30.7 million.

Cash Position and Funding Facility

Net operating cash spend for the half year was US$30.3 million. Mesoblast indicated it expects a reduction in net cash spend over the remainder of FY2026 based on projected quarterly revenue receipts.

The company ended the period with a cash balance of US$130.0 million. It also secured a US$125.0 million five-year non-dilutive credit-line facility, with a second tranche of US$50.0 million available for drawdown until June 30, 2026.

Commercial and Pipeline Developments

As part of its operational update, Mesoblast confirmed that 49 transplant centers have been onboarded for Ryoncil®, with a target of 64 centers representing 94% of U.S. transplants. Coverage by government and commercial payers extends to 280 million U.S. lives.

The company is also progressing lifecycle extension plans for Ryoncil® and advancing development of rexlemestrocel-L in chronic low back pain and chronic heart failure with low ejection fraction.

For FY2026, Mesoblast anticipates Ryoncil® net revenue in the range of US$110 million to US$120 million.

FAQs

What was Mesoblast’s share price on March 4, 2026?
The stock traded at A$2.08, up 3.23% for the day.
How did Mesoblast perform over the past five days?
Despite the daily gain, the shares remain down 13.39% over the last five trading sessions.
What revenue did Mesoblast report for H1 FY2026?
The company reported total revenue of US$51.3 million for the half year ended December 31, 2025.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.